Harmony Biosciences Holdings, Inc. (HRMY) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Plymouth Meeting, PA, 미국. 현재 CEO는 Jeffrey Dayno.
HRMY 을(를) 보유 IPO 날짜 2020-08-19, 268 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $1.69B.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
